Angiotensin II and angiotensin II receptor blocker modulate the arrhythmogenic activity of pulmonary veins

Yi Jen Chen, Yao Chang Chen, Ching Tai Tai, Hung I. Yeh, Cheng I. Lin, Shih Ann Chen

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

1. Angiotensin II receptor blockers (AIIRBs) have been shown to prevent atrial fibrillation. The pulmonary veins (PVs) are the most important focus for the generation of atrial fibrillation. The aim of this study was to evaluate whether angiotensin II or AIIRB may change the arrhythmogenic activity of the PVs. 2. Conventional microelectrodes and whole-cell patch clamps were used to investigate the action potentials (APs) and ionic currents in isolated rabbit PV tissue and single cardiomyocytes before and after administering angiotensin II or losartan (AIIRB). 3. In the tissue preparations, angiotensin II induced delayed after-depolarizations (1, 10, and 100 nM) and accelerated the automatic rhythm (10 and 100 nM). Angiotensin II (100 nM) prolonged the AP duration and increased the contractile force (10 and 100 nM). Losartan (1 and 10 μM) inhibited the automatic rhythm. Losartan (10 μM) prolonged the AP duration and reduced the contractile force (1 and 10 μM). 4. Angiotensin II reduced the transient outward potassium current (I to) but increased the L-type calcium, delayed rectifier potassium (I K), transient inward (I ti), pacemaker, and Na +-Ca 2+ exchanger (NCX) currents in the PV cardiomyocytes. Losartan decreased the I to, I K, I ti, and NCX currents. 5. In conclusion, angiotensin II and AIIRB modulate the PV electrical activity, which may play a role in the pathophysiology of atrial fibrillation.

Original languageEnglish
Pages (from-to)12-22
Number of pages11
JournalBritish Journal of Pharmacology
Volume147
Issue number1
DOIs
Publication statusPublished - Jan 2006

Fingerprint

Pulmonary Veins
Angiotensin Receptor Antagonists
Angiotensin II
Losartan
Sodium-Calcium Exchanger
Atrial Fibrillation
Action Potentials
Cardiac Myocytes
Potassium
Microelectrodes
Rabbits
Calcium

Keywords

  • Angiotensin II
  • Atrial fibrillation
  • Ionic currents
  • Pulmonary vein

ASJC Scopus subject areas

  • Pharmacology

Cite this

Angiotensin II and angiotensin II receptor blocker modulate the arrhythmogenic activity of pulmonary veins. / Chen, Yi Jen; Chen, Yao Chang; Tai, Ching Tai; Yeh, Hung I.; Lin, Cheng I.; Chen, Shih Ann.

In: British Journal of Pharmacology, Vol. 147, No. 1, 01.2006, p. 12-22.

Research output: Contribution to journalArticle

Chen, Yi Jen ; Chen, Yao Chang ; Tai, Ching Tai ; Yeh, Hung I. ; Lin, Cheng I. ; Chen, Shih Ann. / Angiotensin II and angiotensin II receptor blocker modulate the arrhythmogenic activity of pulmonary veins. In: British Journal of Pharmacology. 2006 ; Vol. 147, No. 1. pp. 12-22.
@article{bf9a6a25f9854df586873bcdab1c9a40,
title = "Angiotensin II and angiotensin II receptor blocker modulate the arrhythmogenic activity of pulmonary veins",
abstract = "1. Angiotensin II receptor blockers (AIIRBs) have been shown to prevent atrial fibrillation. The pulmonary veins (PVs) are the most important focus for the generation of atrial fibrillation. The aim of this study was to evaluate whether angiotensin II or AIIRB may change the arrhythmogenic activity of the PVs. 2. Conventional microelectrodes and whole-cell patch clamps were used to investigate the action potentials (APs) and ionic currents in isolated rabbit PV tissue and single cardiomyocytes before and after administering angiotensin II or losartan (AIIRB). 3. In the tissue preparations, angiotensin II induced delayed after-depolarizations (1, 10, and 100 nM) and accelerated the automatic rhythm (10 and 100 nM). Angiotensin II (100 nM) prolonged the AP duration and increased the contractile force (10 and 100 nM). Losartan (1 and 10 μM) inhibited the automatic rhythm. Losartan (10 μM) prolonged the AP duration and reduced the contractile force (1 and 10 μM). 4. Angiotensin II reduced the transient outward potassium current (I to) but increased the L-type calcium, delayed rectifier potassium (I K), transient inward (I ti), pacemaker, and Na +-Ca 2+ exchanger (NCX) currents in the PV cardiomyocytes. Losartan decreased the I to, I K, I ti, and NCX currents. 5. In conclusion, angiotensin II and AIIRB modulate the PV electrical activity, which may play a role in the pathophysiology of atrial fibrillation.",
keywords = "Angiotensin II, Atrial fibrillation, Ionic currents, Pulmonary vein",
author = "Chen, {Yi Jen} and Chen, {Yao Chang} and Tai, {Ching Tai} and Yeh, {Hung I.} and Lin, {Cheng I.} and Chen, {Shih Ann}",
year = "2006",
month = "1",
doi = "10.1038/sj.bjp.0706445",
language = "English",
volume = "147",
pages = "12--22",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Angiotensin II and angiotensin II receptor blocker modulate the arrhythmogenic activity of pulmonary veins

AU - Chen, Yi Jen

AU - Chen, Yao Chang

AU - Tai, Ching Tai

AU - Yeh, Hung I.

AU - Lin, Cheng I.

AU - Chen, Shih Ann

PY - 2006/1

Y1 - 2006/1

N2 - 1. Angiotensin II receptor blockers (AIIRBs) have been shown to prevent atrial fibrillation. The pulmonary veins (PVs) are the most important focus for the generation of atrial fibrillation. The aim of this study was to evaluate whether angiotensin II or AIIRB may change the arrhythmogenic activity of the PVs. 2. Conventional microelectrodes and whole-cell patch clamps were used to investigate the action potentials (APs) and ionic currents in isolated rabbit PV tissue and single cardiomyocytes before and after administering angiotensin II or losartan (AIIRB). 3. In the tissue preparations, angiotensin II induced delayed after-depolarizations (1, 10, and 100 nM) and accelerated the automatic rhythm (10 and 100 nM). Angiotensin II (100 nM) prolonged the AP duration and increased the contractile force (10 and 100 nM). Losartan (1 and 10 μM) inhibited the automatic rhythm. Losartan (10 μM) prolonged the AP duration and reduced the contractile force (1 and 10 μM). 4. Angiotensin II reduced the transient outward potassium current (I to) but increased the L-type calcium, delayed rectifier potassium (I K), transient inward (I ti), pacemaker, and Na +-Ca 2+ exchanger (NCX) currents in the PV cardiomyocytes. Losartan decreased the I to, I K, I ti, and NCX currents. 5. In conclusion, angiotensin II and AIIRB modulate the PV electrical activity, which may play a role in the pathophysiology of atrial fibrillation.

AB - 1. Angiotensin II receptor blockers (AIIRBs) have been shown to prevent atrial fibrillation. The pulmonary veins (PVs) are the most important focus for the generation of atrial fibrillation. The aim of this study was to evaluate whether angiotensin II or AIIRB may change the arrhythmogenic activity of the PVs. 2. Conventional microelectrodes and whole-cell patch clamps were used to investigate the action potentials (APs) and ionic currents in isolated rabbit PV tissue and single cardiomyocytes before and after administering angiotensin II or losartan (AIIRB). 3. In the tissue preparations, angiotensin II induced delayed after-depolarizations (1, 10, and 100 nM) and accelerated the automatic rhythm (10 and 100 nM). Angiotensin II (100 nM) prolonged the AP duration and increased the contractile force (10 and 100 nM). Losartan (1 and 10 μM) inhibited the automatic rhythm. Losartan (10 μM) prolonged the AP duration and reduced the contractile force (1 and 10 μM). 4. Angiotensin II reduced the transient outward potassium current (I to) but increased the L-type calcium, delayed rectifier potassium (I K), transient inward (I ti), pacemaker, and Na +-Ca 2+ exchanger (NCX) currents in the PV cardiomyocytes. Losartan decreased the I to, I K, I ti, and NCX currents. 5. In conclusion, angiotensin II and AIIRB modulate the PV electrical activity, which may play a role in the pathophysiology of atrial fibrillation.

KW - Angiotensin II

KW - Atrial fibrillation

KW - Ionic currents

KW - Pulmonary vein

UR - http://www.scopus.com/inward/record.url?scp=30344463005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30344463005&partnerID=8YFLogxK

U2 - 10.1038/sj.bjp.0706445

DO - 10.1038/sj.bjp.0706445

M3 - Article

C2 - 16273119

AN - SCOPUS:30344463005

VL - 147

SP - 12

EP - 22

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 1

ER -